Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 20INDUSTRY 2OTHER_GOV 1NIH 1

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 3216Carcinoma, Non-Small-Cell Lung 2729Breast Neoplasms 2551Colorectal Neoplasms 1463Prostatic Neoplasms 1307Neoplasm Metastasis 1301Multiple Myeloma 1112Melanoma 1103Ovarian Neoplasms 1006Lung Neoplasms 945Recurrence 924Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 833Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 692Carcinoma, Renal Cell 660Carcinoma, Hepatocellular 647Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 515Head and Neck Neoplasms 490Glioblastoma 473Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 436Advanced Solid Tumors 432Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Interventions

sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Liver Failure × Clear all
NCT04617522 2026-06-02

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Gilead Sciences

Phase 1 Recruiting
30 enrolled

Neoplasm Metastasis, Liver Failure

NCT01452295 2013-12-04

Registry Protocol for Tracking Trial Subjects After VTI-206 Study Completion

Vital Therapies, Inc.

Phase 2/3 Withdrawn

Hepatitis, Alcoholic, Liver Failure, Liver Failure, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡